Biomarkers for Response to TIL Therapy: a Comprehensive Review

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Mar 14

PMID 38485186

Authors

Victor Albarran Fernandez

Pablo Ballestin Martinez

Joachim Stoltenborg Granhoj

Troels Holz Borch

Marco Donia

Inge Marie Svane

Affiliations

Soon will be listed here.

Abstract

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4 ratio, ex vivo culture time, expression of exhaustion markers, costimulatory signals, antitumor reactivity, and scope of target tumor-associated antigens), and other treatment-related factors (such as lymphodepleting chemotherapy and postinfusion administration of interleukin-2).

Citing Articles

Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.

Wu S, Thawani R Cancers (Basel). 2025; 17(5).

PMID: 40075649 PMC: 11899253. DOI: 10.3390/cancers17050801.

Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.

Zhang D, Liu G, Ye J, Li K, Zhang G, Quan Q BMC Cancer. 2025; 25(1):178.

PMID: 39885493 PMC: 11783800. DOI: 10.1186/s12885-025-13497-2.

Unlocking the potential of engineered immune cell therapy for solid tumors.

Albarran-Fernandez V, Angelats L, Delgado J, Gros A, Urbano-Ispizua A, Guedan S Nat Commun. 2025; 16(1):1144.

PMID: 39880825 PMC: 11779857. DOI: 10.1038/s41467-025-56527-0.

Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity.

Ren X Cancer Biol Med. 2024; 22(1).

PMID: 39663761 PMC: 11795261. DOI: 10.20892/j.issn.2095-3941.2024.0453.

Cancer Vaccines: Recent Insights and Future Directions.

Malacopol A, Holst P Int J Mol Sci. 2024; 25(20).

PMID: 39457036 PMC: 11508577. DOI: 10.3390/ijms252011256.

References

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

Yao X, Ahmadzadeh M, Lu Y, Liewehr D, Dudley M, Liu F . Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012; 119(24):5688-96. PMC: 3382928. DOI: 10.1182/blood-2011-10-386482. View

Kristensen N, Heeke C, Tvingsholm S, Borch A, Draghi A, Crowther M . Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J Clin Invest. 2021; 132(2). PMC: 8759789. DOI: 10.1172/JCI150535. View

Klebanoff C, Khong H, Antony P, Palmer D, Restifo N . Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005; 26(2):111-7. PMC: 1388277. DOI: 10.1016/j.it.2004.12.003. View

Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine M . Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab. 2017; 25(6):1282-1293.e7. PMC: 5462872. DOI: 10.1016/j.cmet.2016.12.018. View

Hernandez-Chacon J, Li Y, Wu R, Bernatchez C, Wang Y, Weber J . Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011; 34(3):236-50. PMC: 3063939. DOI: 10.1097/CJI.0b013e318209e7ec. View

Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell Jr D, Wunderlich J, Merino M . FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 2008; 112(13):4953-60. PMC: 2954707. DOI: 10.1182/blood-2008-06-163048. View

Shin S, Kim Y, Choi B, Kwon P, Lee H, Kwon B . 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol. 2007; 81(6):1455-65. DOI: 10.1189/jlb.1006619. View

10.

Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H . Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021; 39(24):2656-2666. PMC: 8376325. DOI: 10.1200/JCO.21.00612. View

11.

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

12.

Holz Borch T, Andersen R, Ellebaek E, Met O, Donia M, Marie Svane I . Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer. 2020; 8(2). PMC: 7398110. DOI: 10.1136/jitc-2020-000668. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Nguyen L, Saibil S, Sotov V, Le M, Khoja L, Ghazarian D . Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother. 2019; 68(5):773-785. PMC: 11028227. DOI: 10.1007/s00262-019-02307-x. View

15.

Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M . Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991; 83(13):932-7. DOI: 10.1093/jnci/83.13.932. View

16.

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F . Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017; 8(1):1738. PMC: 5701046. DOI: 10.1038/s41467-017-01460-0. View

17.

Qui H, Hagymasi A, Bandyopadhyay S, St Rose M, Ramanarasimhaiah R, Menoret A . CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol. 2011; 187(7):3555-64. PMC: 3178659. DOI: 10.4049/jimmunol.1101244. View

18.

Forget M, Haymaker C, Hess K, Meng Y, Creasy C, Karpinets T . Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018; 24(18):4416-4428. PMC: 6139043. DOI: 10.1158/1078-0432.CCR-17-3649. View

19.

Hall M, Teer J, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M . Neoantigen-specific CD4 tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. 2023; 11(10). PMC: 10565316. DOI: 10.1136/jitc-2023-007288. View

20.

Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton J, Curbishley S . Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021; 124(11):1759-1776. PMC: 8144577. DOI: 10.1038/s41416-021-01353-6. View